We haven’t been covering Jim Cramer as much for many different reasons, but we still pay attention when he comes out with stock picks because it can still affect at least the…
There may be some speculation that drug giant Pfizer Inc. (NYSE: PFE) is looking at expansion through acquisitions. The FT reported that the world’s largest pharmaceutical company is willing to acquire a…
People who get to the end of 2008 and are still at work can be thankful. The unemployment rate will probably be over 7%. That does not count the people no longer…
According to Reuters, the Fed may need to use a trillion dollars to halt the economy from moving into a period of deflation. Reuters reports that OPEC will make the largest production…
There are few positive calls this morning from Wall Street analysts, but these are the ones we have caught this morning: Alcatel-Lucent (ALU) Raised to Sector Perform at RBC. ASUR (ASR) Raised…
These are some of the top analyst upgrades we have seen this Friday morning: Abercrombie & Fitch (ANF) Raised to Hold at Jefferies. Bristol-Myers Squibb (BMY) Started as Buy at Goldman Sachs.…
Analysts assume third quarter earnings for the companies in the S&P 500 will be bad. But, looking at the number which is the average of all firms in the index is misleading.…
Carl Icahn appears to have won a blue ribbon for ImClone Systems (NASDAQ: IMCL) shareholders. The biotech stock is trading up on a very weak trading day after what many had deemed…
ImClone Systems Inc. (NASDAQ: IMCL) is among the biotech bonanza merger candidates with one deal on the table and perhaps an unofficial deal waiting in the wings. Bristol-Myers Squibb Co. (NYSE: BMY)…
Douglas A. McIntyre According to Reuters, Wilbur Ross say the bailout package does not address the core of problem which is mortgage payments. Reuters writes that the National Retail Federation says that this will be…
There is some very hopeful data out there this morning on cancer survival. Bristol-Myers Squibb Co. (NYSE: BMY) and Medarex, Inc. (NASDAQ: MEDX) have released updated survival data from three Phase II…
Bristol-Myers Squibb (NYSE: BMY) has sent a letter to Imclone Systems (NASDAQ: IMCL) in response to yesterday’s rejection of its buyout offer. It said it is disappointed that the $60.00 bid was…
Douglas A. McIntyre ImClone Systems Inc. (NASDAQ: IMCL) is a biotech buyout bonanza stock that traders and investors have been watching closely. The company has said that the proposed $60.00 per share cash buyout from…
Douglas A. McIntyre According to Reuters, large Yahoo! (YHOO) holder Capital Research want to know whether vote counts from the company’s annula meeting were accurate. Reuters writes that the Fed is seen as holding rates…
Carl Icahn and friends at ImClone Systems Incorporated (NASDAQ: IMCL) have now formally responded to Bristol-Myers Squibb Company (NYSE: BMY) regarding the cash buyout of the company. The company’s board of directors…
Douglas A. McIntyre